## CAH: Cardinal Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.7% below STRENGTH zone (4.0-10.0%); PEG 1.88 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($191.17)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Cardinal Health (CAH): Assessing Valuation After a Recent Pullback in the Share Price**
- Source: Simply Wall Street | 20251215T150816 | Bullish | Relevance: 100%
- Cardinal Health (CAH) has experienced a recent 4% pullback, creating an interesting setup for investors after a strong year. Despite the dip, the share price remains around $198.18 and analysts consider it undervalued with a fair value near $216.60, driven by expected future earnings strength and operational efficiencies. However, regulatory scrutiny and potential slowdowns in pharma volumes pose risks to these optimistic assumptions.

**2. Cardinal Health (CAH): Assessing Valuation After a Recent Pullback in the Share Price**
- Source: Simply Wall Street | 20251215T144158 | Somewhat-Bullish | Relevance: 100%
- Cardinal Health (CAH) has experienced a recent 4% pullback despite a strong year, leading to investor consideration of its long-term uptrend. The company is perceived as undervalued, with a narrative fair value of $216.60 and an SWS DCF model suggesting an intrinsic value of $461.54, driven by expected operational efficiencies and cash flow improvements from investments in technology and distribution. However, regulatory scrutiny on drug pricing and potential slowdowns in pharma volumes pose risks to optimistic earnings assumptions.

**3. Nomura Holdings Inc. Acquires 72,525 Shares of Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251215T110907 | Bullish | Relevance: 100%
- Nomura Holdings Inc. significantly increased its stake in Cardinal Health, Inc. by 568%, purchasing 72,525 additional shares in Q2, bringing its total holdings to $14.33 million. This comes as Cardinal Health beat Q3 earnings expectations and set strong FY2026 guidance, leading analysts to maintain a "Moderate Buy" rating with an average target price of $209.00. The company also declared a quarterly dividend of $0.5107 per share.

**4. Orion Porfolio Solutions LLC Increases Position in Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251215T122208 | Bullish | Relevance: 100%
- Orion Portfolio Solutions LLC increased its stake in Cardinal Health (NYSE:CAH) by 11% in Q2, acquiring an additional 5,867 shares to hold a total of 59,357 shares valued at approximately $9.97 million. Cardinal Health surpassed quarterly expectations with $2.55 EPS and $64.01 billion in revenue, and has issued a positive FY2026 guidance. Analysts maintain a "Moderate Buy" rating with a consensus price target of $209.00.

**5. Medication Management Market Is Going to Boom |• McKesson Corporation • Cardinal Health**
- Source: openPR.com | 20251215T110038 | Bullish | Relevance: 95%
- Worldwide Market Reports (WMR) projects substantial growth for the Medication Management Market, offering a comprehensive analysis that includes market dynamics, growth drivers, restraints, challenges, opportunities, and competitive landscapes. The report covers key market players like McKesson Corporation and Cardinal Health, along with segmental highlights by types and applications, and provides regional outlooks. It utilizes extensive primary and secondary research to deliver actionable intelligence and growth forecasts for the market from 2025 to 2032.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $243 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 5 ($0.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Blackrock Inc.: 13.2% (+3.0%)
- Vanguard Group Inc: 13.0% (+0.8%)
- State Street Corpora: 5.2% (-3.0%)
- Geode Capital Manage: 2.7% (+1.5%)
- Wellington Managemen: 2.4% (+153.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.88 elevated, pricing in significant growth expectations. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $47.1B |
| Beta | 0.64 |
| 52W Range | $115.00 - $214.93 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.88 |
| Forward P/E | 17.9 |
| Current P/E | 20.2 |
| YoY Growth | 12.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -5.5% to -0.7% (+4.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.7pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.9%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.25x) but short-term weakness (below SMA20). MACD histogram bearish (-1.93), momentum weakening. RSI neutral at 51. OFD pattern: +DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.66% (CS: 26) | Neutral |
| RSI_14 | 50.7 | Neutral |
| MACD Histogram | -1.93 | Bearish |
| vs SMA20 | 0.974x | Below |
| vs SMA50 | 1.054x | Above |
| vs SMA200 | 1.250x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $198.47
- **Stop Loss:** $191.17 (3.7% risk)
- **Target:** $205.77 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 147
- **Position Value:** $29,175.09
- **Portfolio %:** 29.18%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-01-29 (Est: $2.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.17 | $2.55 | +17.3% |
| 2025Q2 | $2.03 | $2.08 | +2.4% |
| 2025Q1 | $2.15 | $2.35 | +9.4% |
| 2024Q4 | $1.76 | $1.93 | +9.4% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_20*